+

WO1986006742A1 - Proteine fusionnee pour des systemes d'essais immunologiques a enzymes - Google Patents

Proteine fusionnee pour des systemes d'essais immunologiques a enzymes Download PDF

Info

Publication number
WO1986006742A1
WO1986006742A1 PCT/US1986/001002 US8601002W WO8606742A1 WO 1986006742 A1 WO1986006742 A1 WO 1986006742A1 US 8601002 W US8601002 W US 8601002W WO 8606742 A1 WO8606742 A1 WO 8606742A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
protein
galactosidase
fused
analyte
Prior art date
Application number
PCT/US1986/001002
Other languages
English (en)
Inventor
Dale B. Schenk
Sharon Kaye Spratt
Original Assignee
California Biotechnology Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Biotechnology Inc. filed Critical California Biotechnology Inc.
Publication of WO1986006742A1 publication Critical patent/WO1986006742A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to enzyme immunoassay systems and. particularly, to a fused protein for use in determination of a peptide or protein analyte in a solid-phase or homogeneous enzyme immunoassay system.
  • Enzyme-labeled antigens are widely used in solid-phase immunoassays, and have been proposed for use in homogeneous immunoassays.
  • the enzyme-labeled antigen is designed to compete with an analyte in solution for binding to anti-analyte binding molecules carried on the surface of a solid support. After the initial competitive-inhibition binding reaction, the solid support is washed and assayed for enzyme activity. The amount of enzyme activity associated with the support is inversely proportional to the amount of analyte present in the original assay reaction mixture.
  • This assay system has the advantage of greater sensitivity over solid-phase immunoassay systems employing antigen/fluorophore or antigen/chromophore conjugates. At the same time, the system avoids the problems and expense involved in measuring radionuclides encountered in solid-phase radioimmune assays (RIA), where the analyte-competing antigen is radiolabeled.
  • RIA radioimmune assays
  • the enzyme-labeled antigen is designed typically to compete with an analyte for binding to an anti-analyte antibody which is free in the reaction mixture.
  • the relative spatial arrangement of antigen and enzyme is such that antibody binding to the antigen produces a measurable, normally inhibitory effect on the enzyme. Therefore, the presence and/or concentration of analyte in solution can be measured as a change in enzyme activity in the assay mixture.
  • a serious limitation of chemical coupling methods is the difficulty in achieving consistent and reproducible antigen/enzyme coupling in terms of (a) the site(s) of antigen attachment to the enzyme, (b) the number of antigens attached to each enzyme molecules, and (c) the extent of loss of enzymz activity or change in im ⁇ iunological activity of the antigen following coupling. Because of the difficulty in controlling these variables, the manufacturer of the assay kit typically must carry out quality control tests on each batch of enzyme-labeled antigen that is produced. Even with the quality controls, it is difficult to predict how variations in antigen binding to an enzyme will affect the enzyme on storage.
  • a homogeneous-type assay may be quite sensitive to variations in the number of antigens bound to the enzyme and/or their sites of attachment, to an extent that many antigen/enzyme reagent for use in a homogeneous assay cannot be produced practically by chemical coupling methods.
  • U.S. Patent No. 4,378,428 describes a homogeneous assay system composed of a peptide antigen fused to a small N-terminal fragment of ⁇ -galactosidase antigen antibody, and a complementary C-terminal ⁇ -galactosidase enzyme fragment, both components produced by recombinant DNA techniques. Binding of an anti-antigen antibody to the fused protein interfers with the ability of the N-terminal portion of the enzyme to form an active enzyme complex with a relatively large C-terminal enzyme fragment.
  • This complementary enzyme system is somewhat expensive to manufacture, and is subject to greater assay variations related to enzyme concentration and stability effects than immunoassays systems employing a single enzyme species.
  • the system would have limited uses in a solid-phase immunoassay, since the amount of enzyme bound to the •solid support could not be assayed directly. It is therefore an object of the present invention to provide a fused enzyme/peptide protein and methods and systems for producing and using the protein, which overcome above-discussed limitations in prior art enzyme immunoassay reagents.
  • the invention includes a fused protein reagent for use in an enzyme immunoassay.
  • the protein includes an enzymatically active ⁇ -galactosidase fused, at its C-terminus, to an immunologically active peptide.
  • the active peptide is preferably derived from an immunologically active region of a peptide hormone, a serum protein, or other suitable polypeptide analyte.
  • the invention further includes a plasmid for use in constructing a fused protein gene.
  • the plasmid contains a complete-sequence ⁇ -galactosidase gene which terminates at a selected restriction endonuclease site.
  • a nucleotide coding for the immunologically active peptide is inserted in the plasmid at the selected restriction site, and a transfected host which produces the desired fused protein is identified by the presence of ⁇ -galactosidase activity and immunospeci ic reaction with an anti-peptide antibody.
  • the fused protein may be used in a solid-phase enzyme immunoassay based on competitive inhibition between an analyte and the fused protein for binding immunospecifically to a solid support.
  • the fused protein forms part of a homogeneous assay system in which antibody binding to the fused protein modulates the protein's enzyme activity.
  • Figure 1 illustrates the construction of a plasmid, designated pG48-4. used in constructing fused proteins according to the present invention, and use of this plasmid in constructing a second plasmid, designated pG4817-4, containing a gene capable of expressing a protein with an immunologically active human surfactant apoprotein (HSA) peptide;
  • HSA human surfactant apoprotein
  • Figure 2 shows levels of specific (open symbols) and non-specific (closed symbols) antisera binding to immobilized ⁇ -galactosidase/HSA peptide fused protein (circles). HSA peptide (squares), and native ⁇ -galactosidase (triangles), expressed as a function of negative log antiserum dilution factor;
  • Figure 3 shows the decrease in enzyme activity associated with a solid support, with increasing amounts of analyte. in a solid-phase competitive inhibition assay;
  • Figure 4 shows the change in enzyme activity, as a function of antibody concentration, in a fused protein used in a homogeneous immunoassay.
  • A. Preparing Plasmid with Complete-Sequence ⁇ -Galacto- sidase Gene To prepare a fused protein according to the invention, there is first constructed a plasmid containing a ⁇ -galactosidase gene which can be expressed in a suitable host as a functionally active enzyme, and which terminates, at its 3' end, at a preferably unique restriction endonuclease site.
  • Plasmids containing the lactose-controlling elements and a major portion of the ⁇ -galactosidase gene from E. coli are available, for example, from J. Shine (reference 2). Generally, these plasmids have a unique restriction endonuclease site, such as an EcoRI site, near the 3' end of the ⁇ -galactosidase gene, and the gene allows expression of a nearly complete but inactive ⁇ -galactosidase enzyme.
  • the plasmid is modified to have a complete or nearly complete ⁇ -galactosidase gene sequence which allows expression of enzymatically active enzyme.
  • This may be done, according to the method of the invention, by constructing a synthetic oligonucleotide which contains the additional 3 '-end codons which are needed for expression of a functionally active protein.
  • the oligonucleotide preferably includes, in addition, one or more sticky ends which (a) permit sticky-end ligation of the insert to the endonuclease-cleaved plasmid, and (b) generate a new, preferably unique, restriction endonuclease site at the insert's 3' end. i.e., the 3' end of the elongated gene.
  • the latter condition may require that the sticky end ligation at the insert's 5' end be such as to eliminate the restriction site at which the plasmid was originally cut.
  • the plasmid and insert ligation products are used to transform a suitable host, such as a ⁇ -galactosidase-deficient E. coli strain, and transformants are selected typically for antibiotic resistance, provided by the replicating plasmid, and for constitutive ⁇ -galactosidase production, as evidenced, for example, by the ability of the colonies to hydrolyze a galactopyranoside substrate which shows an observable color change on enzymatic hydrolysis.
  • the construction of an exemplary plasmid having a' complete-sequence expressible ⁇ -galactosidase gene is illustrated in Figure 1 and detailed in Example I.
  • the pBH20 plasmid used in the construction contains an origin of replication for E.
  • coli ori in Figure 1
  • lac lactose-controlling elements
  • ⁇ -gal ⁇ -galactosidase structural gene.
  • the gene terminates at a unique EcoRI site 17 codons from the 3' end of the complete gene.
  • a plasmid insert containing the 17 missing codons and having EcoRI sticky ends was spliced into the EcoRI site, and the plasmid was used to transform a galactosidase-deficient E. coli strain MC1061.
  • Colonies were selected for ampicillin resistance and blue color in the presence of 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside (X-Gal). evidencing constitutive synthesis of active ⁇ -galactosidase.
  • the ligation eliminated the EcoRI site at the 5' side of the plasmid cut and conserved the EcoRI site on the 3' side of the cut, yielding a plasmid with a complete sequence ⁇ -galactosidase gene which terminates at a unique EcoRI site.
  • the fused protein of the invention contains an immunologically active peptide capable of either inducing antibodies which are cross-reactive with the associated analyte, or which reacts immunospecifically with an anti-analyte antibody.
  • the peptide may be an analyte-like peptide, or derived from an immunologically reactive portion of an analyte.
  • Analytes for which the present invention is applicable include, for example, polypeptide hormones, including angiotensin-II, renin, growth hormone, insulin, glucagon, parathyroid hormone, thyroid stimulating hormone, calcitonin, gastrin, leuteinizing hormone, follicle stimulating hormone, human chorionic gonadotropin, LH releasing hormone and atrial natriuretic factor.
  • polypeptide hormones including angiotensin-II, renin, growth hormone, insulin, glucagon, parathyroid hormone, thyroid stimulating hormone, calcitonin, gastrin, leuteinizing hormone, follicle stimulating hormone, human chorionic gonadotropin, LH releasing hormone and atrial natriuretic factor.
  • polypeptide analytes include large molecular weight proteins (greater than about 10,000 daltons) present in serum or other biological fluids such as amnionic or peritoneal dialysis samples. Proteins in this category include carcinoembryonic antigen, surfactant apoprotein, imraunoglobulins. collagen, transferrin. apoprotein-Al, apoprotein-B, fibronectin, ⁇ -2-macroglobulin, ⁇ -1-antitrypsin, complement C3 and C4, ⁇ -fetoprotein. and peptide inhibitors of phospholipase All. All of these proteins. when present in human serum, are in the concentration
  • Still another class of polypeptide analytes which are suitable for the present invention include surface immunological proteins of pathogenic organisms, such as viral coat proteins.
  • surface immunological proteins of pathogenic organisms such as viral coat proteins.
  • viral coat proteins For a number of viruses, including tobacco mosaic virus, hepatitis B and influenza (references 10-12), detailed studies of the surface coat proteins have indicated a number of immunologically active protein segments from which the fused protein peptide could be derived.
  • Example V below describes the preparation of a fused protein, having, as its immunological peptide, a 29-amino acid segment from influenza virus.
  • a suitable immunologically active peptide is based normally on two- criteria: (a) predicted antigenicity of the peptide, and (b) cross-reactivity of antibodies toward the peptide and analyte.
  • highly charged, hydrophilic peptides are antigenic, and therefore a synthetic peptide is preferably derived from a portion of the antigen which is exposed and/or highly charged.
  • immunologically active regions of a protein are known, these regions will preferably be selected (see. for example, references 3-12).
  • the peptide is first prepared in purified form, according to conventional means, such as by solid-phase synthesis (reference 6).
  • the peptide is used to produce anti-peptide antibodies, for use in selecting plasmid-transfected cells capable of producing the desired fusion protein.
  • the antibodies may also be used in an immunoassay system, to be described below, for determination of the peptide-related analyte.
  • the anti-peptide antibody may be prepared by conventional means, typically using as an immunogen the peptide conjugated to a protein, such as keyhole limpet hemocyanin.
  • the antibody produced may be used in the form of a whole or partially purified antiserum derived from the challenged animal.
  • peripheral lymphocytes isolated from the challenged animals may be fused with a suitable fusion partner to produce monoclonal antibodies, according to well-known techniques (references 14, 15).
  • the binding activity of the antibody toward the peptide and analyte can be confirmed by standard procedures.
  • the methods detailed in Example III for producing anti-HSA peptide antiserum are generally applicable.
  • an oligonucleotide coding for the selected peptide is synthesized for insertion into the above-described plasmid.
  • the oligonucleotide may be constructed conventionally, for example using an automated DNA synthesizer. Typically, where the oligonucleotide contains more than about 30 bases, the synthetic method involves first constructing two or more shorter, overlapping double-stranded nucleotides, and ligating these together to form the final oligonucleotide. This procedure is illustrated in Examples II, IV, and V below.
  • the fully synthesized oligonucleotide preferably includes sticky ends corresponding to the sticky ends created when the ⁇ -galactosidase gene plasmid is cut at its 3' end.
  • the oligonucleotide is inserted at the 3' end of the above plasmid by standard procedures, which involve cutting the plasmid at its unique restriction site adjacent the 3' end of the complete-sequence ⁇ -galactosidase gene, mixing the cut plasmid and peptide-gene insert, ligating, and using the ligation mixture to transform a suitable ⁇ -galactosidase deficient host.
  • Successful transformants are selected on the basis of antibiotic resistance conferred by the plasmid and ⁇ -galactosidase activity.
  • the successful transformants are analyzed for correct insert orientation by standard restriction techniques. These methods are illustrated in Examples II, IV. and V.
  • the selected strain containing the complete-sequence ⁇ -galactosidase gene and correct-orientation peptide insert is examined for expression of the desired ⁇ -galactosidase/peptide fusion protein.
  • the transformed host such as E. coli. is lysed by sonication, and the sonicate examined for molecular-weight distribution of lysate proteins, conventionally by SDS polyacrylamide gel electrophoresis (SDS-PAGE).
  • SDS-PAGE SDS polyacrylamide gel electrophoresis
  • the fused protein of the invention may be purified by standard techniques, and particularly those applicable to the purification of ⁇ -galactosidase (reference 16). Typically, such purification involves an initial ammonium sulfate precipitation, followed successively by ion-exchange and molecular sieve chromatography. The activity of the fused protein-containing fractions is readily followed by the convertion of o-nitrophenol- ⁇ -D-galactoside (ONPG) to the colored product. Representative methods for the purification of a ⁇ -galactosidase/HSA peptide fused protein are described in Example III.
  • immunologically active peptide in fused protein can be confirmed by standard immunological procedures, such as enzyme-linked i munoadsorbent or Ouchterlony fusion analysis.
  • the analyte is allowed to compete with the fused protein for binding to a solid support coated with an antibody reactive against both the fused protein and analyte.
  • the antibody-coated support may be prepared by a variety of procedures known in the art for chemically coupling or adsorbing antibody to the surface of a solid support.
  • the surface concentration of antibodies on the solid support is preferably adjusted, in relation to the concentration of fused protein used in the assay, such that the amount of fused protein binding to the solid support is sensitive to the addition of increasing amounts of analyte, within the concentration range of analyte to be tested.
  • the relative concentrations of surface antibody and fused protein are adjusted to produce a level of fused protein binding to» the solid support which is about 50% of the maximum amount of the enzyme that can be bound to the support at high surface-antibody and fused protein concentrations.
  • Such preferred levels of antibody and fused protein can be determined by preparing solid supports having a range of different antibody concentrations and incubating each of these with a range of protein concentrations, as detailed in Example VI.
  • the solid support is added to a reaction mixture containing the selected concentration of fused protein, and one of a series of different concentrations of the analyte to be determined.
  • the reaction mixture is incubated under conditions which allow equilibration of analyte and fused protein binding to the solid support, typically at room temperature for 30 min.
  • the support is separated from the liquid reaction mixture, and the solid support is washed one or more times to remove nonspecifically bound material.
  • the ⁇ -galactosidase activity associated with the solid support is measured conveniently by placing the support in an assay mixture containing a suitable enzyme substrate.
  • a suitable enzyme substrate is ONPG, whose hydrolysis by ⁇ -galactosidase produces a yellow-green color reaction which can be monitored at 495 nm.
  • the solid-phase immunoassay just described is illustrated in Example VI below, which describes a procedure for determination of human surfactant apoprotein.
  • the results of the assay are plotted in Figure 3 as percent change in ⁇ -galactosidase activity associated with the solid support as a function of the log of the amount of human surfactant apoprotein assayed.
  • the plot is substantially linear in the analyte range between 1 and 100 nanagrams. and within this range, the total enzyme activity associated with this solid support declines more than 80%.
  • the test is sensitive to about 5 nanagrams of analyte.
  • the use of the above fused protein in a homogeneous immunoassay requires that the protein show a measurable enzyme activity effect with antibody binding to the peptide moiety in the protein.
  • the inhibitory effect achievable by antibody binding to the fused protein will depend on such factors as the size of the peptide and the proximity of the immunogenic region of the peptide to the enzyme-active site, the interaction of the peptide and enzyme in the fused protein, the binding affinity of the antibody for the peptide, and the relative concentration of antibody and fused protein. To some extent, these factors can be controlled to optimize the inhibitory effect produced by antibody binding to the fused protein.
  • the antibody-inhibition effect will be enhanced where the peptide is relatively short, e.g., less than about 20 amino acids, or where the immunologically active region of the peptide is adjacent the enzyme/peptide fusion junction.
  • Example VII The inhibitory effect of antibody binding to a fused protein constructed according to the invention is illustrated in Example VII, which examines the inhibitory effect of anti-HSA antiserum. at a variety of antiserum dilutions, on the ⁇ -galactosidase activity in a ⁇ -galactosidase/HSA peptide fused protein. Percent enzyme inhibition as a function of antiserum dilution is plotted in Figure 4. The figure shows that the enzymatic activity of the fusion protein can be inhibited significantly (about 40%) by antibody binding, and that optimal relative concentrations of fused protein and antibody are important in achieving a maximal inhibitory effect.
  • the homogeneous assay may be used for determination either of an anti-peptide antibody analyte. based on direct inhibition of the fused protein enzyme activity by analyte binding, or may be based on competitive inhibition of the analyte for binding to an anti-peptide antibody.
  • direct-inhibition immunoassay the fused protein is incubated with serial dilutions of the antibody analyte, under immunoassay reactions conditions like those described above for the solid-phase assay. Following the reaction incubation step, the samples are assayed for ⁇ -galactosidase activity.
  • Example VII illustrates this type of assay for determination for anti-HSA antibody.
  • the fused protein and anti-peptide antibody are incubated with serially diluted amounts of the analyte, also under incubation conditions like those described above.
  • analyte binding to the antibody in solution decreases the amount of antibody available to the fused protein, producing a reduction in the inhibitory effect seen in the absence of analyte.
  • the data from Figure 4 indicate that relative concentrations of fused protein and antibody corresponding to an antiserum dilution of 1:10,000 in Figure 4 would be optimal, since a relatively low concentrations of analyte would be effective to increase enzyme activity measurably above the 60% inhibition level seen in the absence of analyte. From the foregoing, it can be appreciated how various objects and features of the invention are met.
  • the plasmid of the invention containing a complete-sequence ⁇ -galactosidase gene which terminates at its -3' end in a unique restriction endonuclease site, permits a fused protein gene to be constructed readily by insertion at the restriction site of an oligonucleotide coding for a selected peptide.
  • the plasmid containing the fused protein gene can be used, in a suitable host, for producing a fused protein having homogeneous and predictable characteristics.
  • the fused protein when used in a solid-phase immunoassay system, is capable of producing a highly sensitive linear-range assay for determination of a polypeptide analyte.
  • the fused protein forms part of a homogeneous immunoassay system for use either in the determination of an anti-peptide antibody analyte or or determination of an antigenic polypeptide analyte by competitiveinhibition binding to a soluble antibody also forming part of the assay system.
  • DNA cleavage is performed by treating with EcoRI under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of the commercially available enzyme. See, e.g.. New England Biolabs, Product Catalog.
  • EcoRI EcoRI under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of the commercially available enzyme. See, e.g.. New England Biolabs, Product Catalog.
  • about 1 ⁇ g of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 ⁇ l of buffer solution; in the examples herein, typically an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour or two hours at about 37°C are workable, although variations can be tolerated.
  • cleaved fragments After each incubation, protein is removed by extractions with phenol/chloroform, and may be followed by ether extration, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. Ligations are performed typically in 15-30 ⁇ l volumes under the following standard conditions and temperatures: 50 mM Tris-Cl, pH 7.5, 10 M MgCl . 10 mM DTT, 100 ⁇ g/ml BSA.
  • CIP digestions are conducted typically at about pH 9, in
  • Mg Mg . using about 0.01 unit of CIP per ⁇ g of vector. depending on size, at 37°C for about one hour.
  • the preparation is extracted with phenol/chloroform and ethanol precipitation.
  • religation can be prevented in vectors which have been double-digested by additional restriction enzyme digestion of the unwanted fragments.
  • Plasmid pBH20 the construction of which is described in reference 2. was obtained from J. Shine at
  • This plasmid contains the nucleotide sequence for the lactose controlling element and all but the last 51 nucleotides of the ⁇ -galactosidase structural gene.
  • the plasmid contains a unique EcoRI site at codon 1004 of the ⁇ -galactosidase gene, 17 codons from the 3' end of the gene.
  • the plasmid was modified by inserting, at the
  • a gene fragment coding for these 17 amino acids and having EcoRI sticky ends was prepared from the six overlapping oligonucleotides A-F:
  • oligonucleotide was synthesized on a SAM I automated DNA synthesizer (Biosearch, San Rafael, CA) and purified by preparative gel elctrophoresis. Oligonucleotides (5 ⁇ g) were phosphorylated at the 5' end with T4 polynucleotide kinase using the procedure of Maniatis et al (reference 17). Oligonucleotides A and F were not phosphorylated, thereby preventing unwanted polymerization of these fragments at their complementary ends. Phosphorylated and nonphosphorylated oligonucleotides were mixed and annealed at 100°C for 5 min in a reaction mixture containing 66 mM Tris-HCl, pH 7.5.
  • the reaction was cooled to 25°C for 1 hr followed by the addition of T4 DNA ligase and 10 mM dithiothreitol and an additional 16 hr incubation at 12.5°C.
  • the ligation reaction was analyzed by autoradiography of a sample after polyacryla ide gel electrophoresis. DNA fragments corresponding to the entire insert, as judged by their migration and apparent molecular weight, were eluted from the gel overnight at 65°C using DNA elution buffers as described by Maxam (reference 18).
  • the final insert has the sequence:
  • the synthetic ⁇ -galactosidase DNA fragment from above was ligated into EcoRI-digested pBH20 according to the Applicable Methods described above.
  • the ligation mix was used to transform the galactosidase-deficient E. coli MC1061. obtained from M. Casadaban.
  • Transformants were selected for ampicillin resistance on minimal media plates containing 100 ⁇ g/ml ampicillin and 40 ⁇ g/ml of 5-bromo-4-chloro-3-indolyl- ⁇ -D-galac opyranoside (X-Gal). Colonies constitutive for the synthesis of enzymatically active galactosidase were identified by their blue color (due to the hydrolysis of the X-Gal).
  • HSA Human surfactant apoprotein
  • oligonucleotides were synthesized, purified, isolated, and ligated, as described above. Following ligation, an annealed 48 base pair DNA fragment having the following base sequence was isolated:
  • This DNA fragment contains an AATT 5' EcoRI sticky end. the 12 codons corresponding to the 12 amino acids in the surfactant apoprotein peptide segment, a TAA termination codon. and a 3 '-end TTAA EcoRI sticky end.
  • the synthetic peptide DNA fragment was ligated to EcoRI-digested pG48-4 under conditions described in the Applicable Methods.
  • the resulting plasmid preparation was transfected into the MC1061 strain of E. coli. The bacteria were grown on minimal media containing ampicillin and X-Gal (40 ⁇ g/ml). Transformants with ⁇ -galactosidase activity (blue colonies) were selected and examined for the insertion of 48 base pair EcoRI fragment.
  • E. coli strain M1061 transformed with pG4817-4 was grown, lysed by sonication, and examined by SDS-polyacrylamide gel electrophoresis, as described generally in reference 19.
  • the strain transformed with the plasmid pG48-4 (encoding for native ⁇ -galactosidase only) contained a protein with an apparent molecular weight of 116,000 daltons.
  • a ⁇ -galactosidase fusion protein produced by the bacterial strain transformed with pG4817-4 migrated with an apparent molecular weight of 118,000 daltons.
  • the control MC1061, lacking a pG48-4 plasmid. did not produce proteins of apparent molecular weight in the range 116,000-118,000 daltons.
  • ⁇ -Galactosidase/HSA Peptide Fusion Protein The ⁇ -galactosidase fusion protein from Example III was purified from lysed E. coli cell supernatant according to procedures described by Cravan et al
  • the purification procedure employes the following steps: (1) 50% ammonium sulfate precipitation and dialysis, (2) Sephadex G-200 chromatography, and (3) ion exchange at pH 7.6 with a linear NaCl gradient (0-5%) on DEAE-Sephacel. All procedures were performed at 4°C and storage of pooled ⁇ -galactosidase activity was always in a solution of 50%-saturated ammonium sulfate.
  • the buffer used throughout the purification procedure was 0.1 M histidine, 10 mM MgCl , and 10 mM ⁇ -mecaptoethanol.
  • the presence of the ⁇ -galactosidase fusion protein was followed by analyzing an aliquot of each fraction for its ability to convert ONPG to a colored product.
  • a liter of media yielded 1-2 mg of enzyme with a specific activity of 320-360 unfts/mg protein (> 95% pure).
  • HSA peptide sequence on the ⁇ -galactosidase fusions protein was confirmed immunologically.
  • Rabbit antiserum directed against the surfactant apoprotein 13-mer peptide was obtained by the following procedures. The peptide was first synthesized by solid-phase techniques (reference 13). The complete peptide was cleaved from the resin with 32 M hydrogen fluoride. The resulting crude peptide was further purified by DEAE-Sephacel chromatography using a combined pH and salt gradient (10 mM ammonium acetate, pH 8.0, to 0.2 M ammonium acetate, pH 6.0).
  • HSA peptide (5 mg) was conjugated to keyhole limpet hemocyanin (KLH) with carbodiimide using a two-step precedure. Peptide and 5 mg of carbodiimide were incubated in 1 ml of 1 mM HCl for 15 min at 4°C. Nine ml of 1 mM NaOH (25°C) were added to this mixture followed by 5 mg of KLH. THe reaction mixture was shaken overnight at 21°C and dialyzed against 10 mM NaH PO . 150 mM NaCl (pH 7.4) for 2 days.
  • KLH keyhole limpet hemocyanin
  • the HSA peptide/KLH conjugate was emulsified in a 4:6 ratio with complete Freund's adjuvant and 50 ⁇ g protein were injected into 5 kg Male Dutch belted rabbits in the footpads. The rabbits were boosted with the same preparation i.m. in their hindlegs 3 weeks later. Ten days later the animals were bled and antiserum was collected and analyzed. Using standard enzyme-linked immunoadsorbent assays (reference 1). the ability of the antipeptide and control antisera to bind to various antigens was investigated.
  • a plot of antibody binding to (a) the ⁇ -galactosidase fusion protein (circles), (b) the surfactant apoprotein peptide alone (squares), (c) native ⁇ -galactosidase (diamonds), and (d) binding of ⁇ -galactosidase fusion protein to non-immune serum (closed circles) is shown in Figure 2.
  • the binding of the fused protein to antiserum was substantially greater than binding of the antiserum to the peptide alone (with an apparent titer of 1:1000).
  • the two controls involving native enzyme binding to antipeptide antiserum and fusion protein binding to non-immune serum both gave low background levels.
  • Atrial Natriuretic Factor Fused Protein Human atrial natriuretic factor (ANF) consists of an antigenic peptide containing the following amino acid sequence:
  • oligonucleotides having EcoRI sticky ends are synthesized, purified, isolated and ligated as described above. As constructed, this DNA fragment contains a 5' EcoRI sticky end, 25 codons. corresponding to the 25 amino acid sequence of ANF, a termination codon and a 3' EcoRI sticky end.
  • the synthetic peptide fragment is ligated into EcoRI digested pG48-4 and then transfected into the MC1061 strain of E. coli as described above. Colonies expressing the fused protein are selected, grown and the fusion protein purified as described above. Antibodies are prepared against ANF conjugated to hemocyanin as described above for the HSA peptide. and these together with the fusion protein are used in a competitive inhibition test for ANF. as described for HSA in Example VI, or in a homogeneous immunoassay of the type described in Example VII for HSA.
  • the hemagglutinin protein contained within the influenza virus contains an antigenic locus (HA1) containing the following amino acid sequence:
  • oligonucleotides having EcoRI sticky ends are synthesized, purified, isolated and ligated as described for HSA above.
  • the resulting DNA fragment, having 5' and 3' EcoRI-sticky ends, 23 codons encoding the HA1 0 C-terminus and a termination codon are ligated into EcoRI digested pG48-4 as described above for HSA.
  • the resulting plasmid is transfected into the MC 1061 strain of E. coli and the fused ⁇ -galactoside is purified as described above for the HSA fused protein.
  • Antibodies directed against the HA1 peptide are prepared by synthesizing the peptide by solid phase methods described above and conjugating the peptide to homocyanin for preparation of the immunogen.
  • the HA1 fused protein, together with specific anti-HAl antibodies is used in either a competitive inhibition test or a homogeneous immunoassay for hemagglutinin.
  • HSA ⁇ -galactosidase/HSA peptide fused protein
  • rabbit antiserum against HSA peptide were prepared as described in Example III.
  • HSA was obtained in purified form as described in reference 21.
  • Polystyrene microtiter plates were obtained from Flow Laboratories (Mclean, VA) .
  • a competitive inhibition test for determination of HSA was performed by (a) coating a microtiter dish (the solid support) with anti-HSA peptide antibody, (b) reacting the solid support with the analyte and increasing dilutions of the fused protein, (c) washing the solid support to remove nonspecifically unbound material, and (d) measuring the ⁇ -galactosidase activity associated with the washed support.
  • the assay was carried out at a surface concentration of bound antibodies and added fused protein which resulted in 50% of the maximal enzyme activity achievable by binding maximal amounts of fused protein to the solid support. To achieve this 50% enzyme level, various dilutions (1:100, 1:50.000) of anti-HSA peptide antiserum were coated onto the polystyrene surface of a microtiter dish in 0.1 M
  • microtiter dishes coated with anti-HSA peptide antiserum and washed as described above, were incubated with 15 ng/ml ⁇ -galactosidase/HSA peptide fused protein and 50 ⁇ aliquots of HSA in a total volume of 200 ⁇ in 0.1 M histidine, pH 7.5. 10 mM MgCl for 30 min at 21°C.
  • the total amount of HSA added to the samples ranged from 0.5 to 1000 ng.
  • the plates were washed with the phosphate buffer/TWEEN solution described above and assayed for associated ⁇ -galactosidase activity, as described above.
  • the results obtained, expressed as percent inhibition of enzyme activity are shown in Figure 3.
  • the assay is substantially linear in the analyte range of about 1 and 100 nanogra s HSA, and gives easily observable enzyme inhibition with as little as 5 ng HSA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Une protéine fusionnée utilisée dans un système d'essai immunologique à enzyme comprend une beta-galactosidase à activité enzymatique fusionnée à son terminal C avec un peptide immunologiquement actif. On produit la protéine en utilisant un plasmide contenant un gène complet de beta-galactosidase fusionné à son extrémité 3' avec un oligonucléotide de codage de ce peptide. La protéine fusionnée est utilisée dans un système d'essai immunologique à enzyme, en phase solide, qui fonctionne sur la base d'une immunospécifique de la protéine fusionnée à un support solide, ou dans un système d'essai immunologique homogène à enzyme, qui fonctionne sur la base d'une inhibition d'enzyme provoquée par la liaison immunospécifique d'un anticorps à la protéine.
PCT/US1986/001002 1985-05-07 1986-05-07 Proteine fusionnee pour des systemes d'essais immunologiques a enzymes WO1986006742A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73185385A 1985-05-07 1985-05-07
US731,853 1985-05-07

Publications (1)

Publication Number Publication Date
WO1986006742A1 true WO1986006742A1 (fr) 1986-11-20

Family

ID=24941214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/001002 WO1986006742A1 (fr) 1985-05-07 1986-05-07 Proteine fusionnee pour des systemes d'essais immunologiques a enzymes

Country Status (2)

Country Link
EP (1) EP0222876A1 (fr)
WO (1) WO1986006742A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206769A3 (en) * 1985-06-20 1988-12-28 Fujisawa Pharmaceutical Co., Ltd. A process for the production of alpha-human atrial natriuretic polypeptide
EP0301484A1 (fr) * 1987-07-30 1989-02-01 Gesellschaft für Biotechnologische Forschung mbH (GBF) Modifications de PTH et compositions thérapeutiques les contenant ou composées d'elles
EP0301667A1 (fr) * 1987-07-28 1989-02-01 Istituto Sieroterapico Milanese "S. Belfanti" Méthode d'essai immunologique d'apolipoprotéines
EP0302381A1 (fr) * 1987-08-05 1989-02-08 Chisso Corporation Gène fusionné ayant le gène de l'aequorin unie à un gène fonctionnel de B-galactosidase
FR2648713A1 (fr) * 1989-06-26 1990-12-28 Commissariat Energie Atomique Proteines hybrides entre une enzyme extracytoplasmique et une autre proteine, leur procede de preparation, ainsi que leur application comme agent de diagnostic
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
WO1993007165A1 (fr) * 1991-10-09 1993-04-15 The Scripps Research Institute Dosage lipoproteinique utilisant des anticorps contre tout un epitope natif et des antigenes recombines
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5602015A (en) * 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
EP0688364A4 (fr) * 1993-03-09 1997-10-15 Abbott Lab Enzymes produites par genie genetique et conjugues desdites enzymes pour des analyses diagnostiques
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US6087476A (en) * 1988-03-24 2000-07-11 Igen International, Inc. Luminescent chimeric proteins
EP1182213A1 (fr) * 2000-06-12 2002-02-27 Wako Pure Chemical Industries, Ltd. Une enzyme hybride et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4517290A (en) * 1980-03-31 1985-05-14 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate and antibody therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3654090B1 (fr) * 1968-09-24 1982-07-20
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4517290A (en) * 1980-03-31 1985-05-14 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate and antibody therefor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Enzyme-Immunoassay", E.T. MAGGIO, ed., published 1980, by CRC Press (Boca Raton, Florida), pages 127-130, see especially page 128, 2nd complete paragraph *
CHEMICAL ABSTRACTS, Vol. 102, No. 3, issued 21 January 1985 (Columbus, Ohio, USA), T. PETRI, "Agent for Antigen/Antibody Detection", see page 361, column 1, the Abstract No. 102:20786p, Ger. Offen. DE 3,314,812, 25 October 1984 *
CHEMICAL ABSTRACTS, Vol. 103, No. 21, issued 25 November 1985 (Columbus, Ohio, USA), S. SEIGA et al., "Derivative of Adult T Cell Leukemia Virus Antigen Peptide.", see page 223, column 2-page 224, column 1, Eur. Pat. Appl. EP 152,076, 21 August 1985 *
EMBO, Vol. 1, No. 4, issued 1982, M. KOENEN et al., "Immunoenzymatic Detection of Expressed Gene Fragments in Lac Z Gene of E. Coli," pages 509-512, see Abstract *
EMBO, Vol. 2, No. 10, issued 1983, U. RUTHER et al., "Easy Identification of cDNA Clones," pages 1791-1794, see Abstract *
Gene, Vol. 29, Nos. 1 and 2, issued July/August 1984, A. ULLMAN, "One-step Purification of Hybrid Proteins which have beta-Galactosidase Activity", pages 27-31, see page 27, columns 1 and 2 *
Gene, Vol. 31, Nos. 1-3, issued November 1984, N.P. MINTON, "Improved Plasma Vectors for the Translational Lac Gene Fusions," pages 269-273, see summary Vol. 139 pages 850-858 (Sept. 1978) *
J. Bacteriology, Vol. 143, No. 2, issued August 1980, M. J. CASADABAN et al., "In Vitro Gene Fusions..., "pages 971-980, see Abstract *
Proc. Natl. Acad Sci. USA, Vol. 79, No. 21, issued November 1982, M. R. GRAY, "Open Reading Frame Cloning...," pages 6598-6602, see Abstract *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206769A3 (en) * 1985-06-20 1988-12-28 Fujisawa Pharmaceutical Co., Ltd. A process for the production of alpha-human atrial natriuretic polypeptide
EP0301667A1 (fr) * 1987-07-28 1989-02-01 Istituto Sieroterapico Milanese "S. Belfanti" Méthode d'essai immunologique d'apolipoprotéines
WO1989001164A1 (fr) * 1987-07-28 1989-02-09 Baralle Francisco E Procede d'immuno-analyse d'apolipoproteines
EP0301484A1 (fr) * 1987-07-30 1989-02-01 Gesellschaft für Biotechnologische Forschung mbH (GBF) Modifications de PTH et compositions thérapeutiques les contenant ou composées d'elles
EP0302381A1 (fr) * 1987-08-05 1989-02-08 Chisso Corporation Gène fusionné ayant le gène de l'aequorin unie à un gène fonctionnel de B-galactosidase
US6087476A (en) * 1988-03-24 2000-07-11 Igen International, Inc. Luminescent chimeric proteins
US5602015A (en) * 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5534223A (en) * 1989-06-26 1996-07-09 Commissariat A L'energie Atomique Hybrid proteins between an extracytoplasmic enzyme and at least another protein, method for preparing them and also their applications
EP0407259A1 (fr) * 1989-06-26 1991-01-09 Commissariat A L'energie Atomique Protéines hybrides entre une enzyme extracytoplasmique et au moins une autre protéine, leur procédé de préparation, ainsi que leurs applications
US5362644A (en) * 1989-06-26 1994-11-08 Commissariat A L'energie Atomique Hybrid proteins between an extracytoplasmic enzyme and at least another protein, method for preparing them and also their applications
FR2648713A1 (fr) * 1989-06-26 1990-12-28 Commissariat Energie Atomique Proteines hybrides entre une enzyme extracytoplasmique et une autre proteine, leur procede de preparation, ainsi que leur application comme agent de diagnostic
WO1993007165A1 (fr) * 1991-10-09 1993-04-15 The Scripps Research Institute Dosage lipoproteinique utilisant des anticorps contre tout un epitope natif et des antigenes recombines
EP0688364A4 (fr) * 1993-03-09 1997-10-15 Abbott Lab Enzymes produites par genie genetique et conjugues desdites enzymes pour des analyses diagnostiques
EP1182213A1 (fr) * 2000-06-12 2002-02-27 Wako Pure Chemical Industries, Ltd. Une enzyme hybride et son utilisation

Also Published As

Publication number Publication date
EP0222876A1 (fr) 1987-05-27

Similar Documents

Publication Publication Date Title
US4745055A (en) Fused protein for enzyme immunoassay system
EP0711303B1 (fr) Biotinylation de proteines
WO1986006742A1 (fr) Proteine fusionnee pour des systemes d'essais immunologiques a enzymes
JP2562286B2 (ja) タンパク質結合酵素相補性検定に関する方法
US20120149870A1 (en) Sequentially arranged streptavidin-binding modules as affinity tags
EP0551842A2 (fr) Polypeptides donneurs d'enzyme et accepteurs d'enzyme et vecteur d'ADN recombinant comprenant un codage ADN pour de tels polypeptides
AU600439B2 (en) Ras oncogene peptides and antibodies
AU2002254683A1 (en) Binding molecules for Fc-region polypeptides
WO2002086070A2 (fr) Molecules de liaison pour les polypeptides de zone fc
EP0514173B1 (fr) Méthodes et composés pour des essais de complémentation d'enzyme utilisant la région omega de bêta-galactosidase
US5731427A (en) Nucleic acids encoding a gap-associated protein
Gillet et al. Insertion of a disulfide-containing neurotoxin into E. coil alkaline phosphatase: the hybrid retains both biological activities
US5888775A (en) Peptide synthesis and purification by fusion to penI protein or precipitation effective portion thereof
JP2000023684A (ja) タンパク質結合酵素の相補性アッセイのための方法
Peaucellier et al. Anti‐peptide Antibody Identifies a 57 kDa Protein Tyrosine Kinase in the Sea Urchin Egg Cortex: (tyrosine kinase/fertilization/src/egg/antibody)
US6986994B2 (en) INGAP displacement assays
CA2642066C (fr) Fragments immuno-interactifs de la sous-unite .alpha.c de l'inhibine
Glass et al. Antibodies against Synthetic Phosphorylation Site Peptides
EP1130030A1 (fr) Facteur associé à la différentiation érytroide
Matikainen et al. Monoclonal antibodies against human osteocalcin made by using recombinant GST-rhOC as an immunogen
Wang et al. Antibodies directed against synthetic peptides distinguish between the catalytic subunits of protein phosphatases 1 and 2A
CN115925836A (zh) 一种重组链霉亲和素、其编码基因、重组质粒和基因工程菌及其应用
JP2001046087A (ja) リボ核タンパク質の組換え製造方法
AU1007801A (en) Immuno-interactive fragments of the alphac subunit of inhibin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载